Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Revenue of Sera Prognostics, Inc. (SERA)
Revenue in 2023 (TTM): $306 K
According to Sera Prognostics, Inc.'s latest financial reports the company's current revenue (TTM) is $306 K. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Sera Prognostics, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $306 K | $-804,000 | $-38,621,000 | $-36,242,000 | $-36,242,000 |
| 2022 | $268 K | $75 K | $-44,125,000 | $-44,186,000 | $-44,247,000 |
| 2021 | $82 K | $45 K | $-34,263,000 | $-35,009,000 | $-36,228,000 |
| 2020 | $25 K | $14 K | $-17,114,000 | $-19,848,000 | $-21,607,000 |
| 2019 | $36 K | $18 K | $-13,603,000 | $-16,521,000 | $-20,439,000 |